The HSV-2 mutant ΔPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins
- 1 October 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 17 (3), 315-327
- https://doi.org/10.1038/gt.2009.126
Abstract
Malignant melanoma is a highly aggressive and drug-resistant cancer. Virotherapy is a novel therapeutic strategy based on cancer cell lysis through selective virus replication. However, its clinical efficacy is modest, apparently related to poor virus replication within the tumors. We report that the growth compromised herpes simplex virus type 2 (HSV-2) mutant, ΔPK, has strong oncolytic activity for melanoma largely caused by a mechanism other than replication-induced cell lysis. The ratio of dead cells (determined by trypan blue or ethidium homodimer staining) to cells that stain with antibody to the major capsid protein VP5 (indicative of productive infection) was 1.8–4.1 for different melanoma cultures at 24–72 h post-infection. Cell death was due to activation of calpain as well as caspases-7 and -3 and it was abolished by the combination of calpain (PD150606) and pancaspase (benzyloxycarbonyl-Val-Ala-Asp-fluormethyl ketone, z-VAD-fmk) inhibitors. Upregulation of the autopahgy protein Beclin-1 and the pro-apoptotic protein H11/HspB8 accompanied ΔPK-induced melanoma oncolysis. Intratumoral ΔPK injection (106–107 plaque-forming unit (pfu)) significantly reduced melanoma tumor burden associated with calpain and caspases-7 and -3 activation, Beclin-1 and H11/HspB8 upregulation and activation of caspase-1-related inflammation. Complete remission was seen for 87.5% of the LM melanoma xenografts at 5 months after treatment termination. The data indicate that ΔPK is a promising virotherapy for melanoma that functions through virus-induced programmed cell death pathways.This publication has 66 references indexed in Scilit:
- Targeted Peptidecentric Proteomics Reveals Caspase-7 as a Substrate of the Caspase-1 InflammasomesMolecular & Cellular Proteomics, 2008
- Executioner caspase-3 and caspase-7 are functionally distinct proteasesProceedings of the National Academy of Sciences of the United States of America, 2008
- Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replicationCancer Gene Therapy, 2008
- ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+Gene Therapy, 2008
- The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activationCell Death & Differentiation, 2007
- Mechanisms of local immunosuppression in cutaneous melanomaBritish Journal of Cancer, 2007
- The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicityExperimental Neurology, 2007
- Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-β-activated kinase 1Oncogene, 2006
- The growth compromised HSV-2 mutant ΔRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal culturesBrain Research, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America, 2006